Low Enrollment and Reporting of Racial Minorities in Multiple Myeloma Trials – Cancer Therapy Advisor
Minority patients continue to be underrepresented in multiple myeloma trials, in terms of both inclusion and reporting of results.
Related Articles
Gene Expression Score May Guide Treatment in Uveal Melanoma
A gene expression score may be able to predict outcomes of adoptive cell therapy and prevent unnecessary surgeries in patients with uveal melanoma, researchers say.
MRI-Guided Neoadjuvant Chemo May Benefit Patients With HR-, HER2+ Breast Cancer
Early data suggest that using MRI to guide neoadjuvant chemotherapy may be beneficial for patients with stage II-III, HR-, HER2+ breast cancer.
Cancer Survivors Have Higher Risk of Functional Disability
US cancer survivors are more likely than the general population to have a mobility or self-care disability, a large study suggests.
Corrections, Retractions Issued for Papers by Dana-Farber Researchers
Several corrections and retractions have been issued for study reports written by researchers at the Dana-Farber Cancer Institute since errors in these and other papers…
Trastuzumab Deruxtecan May Fulfill Unmet Need in HER2-Overexpressing NSCLC
Trastuzumab deruxtecan demonstrated activity in a phase 2 trial of patients with HER2-overexpressing, relapsed/refractory, unresectable and/or metastatic NSCLC.
American Association for Cancer Research Annual Meeting Archives
Close more info about Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers Close more info about Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive
Does Fracking Cause Cancer?
There are only a few studies investigating whether fracking may cause cancer, so more research is needed to draw a definitive conclusion, said Nicole Deziel,…
Saruparib Appears Safe, Active in Advanced Breast Cancer
Saruparib may be safe and effective for patients with homologous recombination repair-deficient, HER2-negative breast cancer.
Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers
Alectinib has demonstrated activity in children with ALK fusion-positive cancers in a phase 1/2 trial.
Olaparib Disappoints as Maintenance in Metastatic NSCLC
Adding olaparib to pembrolizumab maintenance did not improve outcomes in patients with metastatic squamous NSCLC in a phase 3 trial.